EXPANSION OF INDUSTRIAL BASE FOR BIOLOGICAL VACCINE PROD

File: 970107_sep96_decls49_0001.txt
Page: 0001
Total Pages: 2

Subject: EXPANSION OF INDUSTRIAL BASE FOR BIOLOGICAL VACCINE PROD        

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003201

Folder Title: EXPANSION OF INDUSTRIAL BASE FOR BIOLOGICAL VACCINE - 3                                         

Document Number:          1

Folder Seq  #:         73



                                 UNCLASSIFIED



                        THE ASSISTANT SECRETARY OF DEFENSE

                              WASHINGTON. D. C. 20301-IZOO

                                                                     NOV im

   HEAETH AFFAIRS





       14EMORANDUM FOR SECRETARY OF THE ARMY

       SUB,7ECT: Expansion of Industrial Base for Biological Vaccine
                Production @


                On October 3, 1990, the Secretary of Defense
       that I take the necessary actions, on a priority basis, to
       acquire second sources to produce biological vaccines to protect
       against anthrax and botulinum toxin (Enclosure 1). To accomplish
       this in an accelerated timeframe, on October 5, 1990, I chartered
       a Tri-Service Task Force to develop short-term options and
       recommendations for increasing vaccine production (Enclosure 2).

                Enclosure 3 is a copy of the Tri-Service Task Force's
       report on the Sho@ Term Production of Anthrax Vaccine.
       Enclosure 4 is a copy of the Tri-Service Task Force's report on
       Short Term Production of Botulinum Toxoid.

                Currently, the Army has a contract with the Michigan
       Department of Public Health in Lansing, Michigan, to produce
       anthrax vaccine and another contract with them to blend available
       botulinum toxoid serotypes into pentavalent botulinum toxoid
       vaccine doses. In addition, Porton International, Inc., of
       Porton Down, United Kingdom, is under contract to the Army to
       produce a serotype F botulinum toxoid; however, human safety
       testing of serotype F has not been initiated.

                After carefully reviewing both of the reports, I request
       that you take the necessary steps, on a priority basis, to carry
       out the following actions:

                 1. Closely monitor the ongoing efforts to increase the
       production capability of the current contractor, Michigan
ing, Michigan. Provide any
       support that may be necessary to ensure that production is
       increased by February 20, 1991.


       Classified by Multiple sources
       Declassify on OADR



        DECLASSIFIED ON 22 NOV 1996 PER OASD (HA) #96-M-0385 PER SEC 3.4 EO 12958


                                   UNCLASSIFIED

Document 2 f:/Week-36/BX003201/EXPANSION OF INDUSTRIAL BASE FOR BIOLOGICAL VACCINE - 3/expansion of industrial base for biological vacc:01029715473950
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003201
Unit = OTSG
Parent Organization = HSC
Folder Title = EXPANSION OF INDUSTRIAL BASE FOR BIOLOGICAL VACCINE - 3
Folder Seq # = 73
Subject = EXPANSION OF INDUSTRIAL BASE FOR BIOLOGICAL VACC
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 02-JAN-1997